We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...

Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $72.34, a high estimate of $183.00, and a low estimate of $10.00. Highlighting a 37.16% decrease, the current ...

Fintel reports that on June 25, 2025, HC Wainwright & Co. downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Neutral to Sell. Analyst Price Forecast Suggests 209.90% Upside As of ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers.

Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...

Wave Life Sciences Ltd. shows promise with AATD, DMD, and Huntington's programs. Click for my updated look at WVE stock and ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") ( NASDAQ: SRPT) on behalf ...